The latest price target for Artiva Biotherapeutics (NASDAQ:ARTV) was reported by Needham on June 8, 2026. The analyst firm set a price target for $41.00 expecting ARTV to rise to within 12 months (a possible 303.15% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Artiva Biotherapeutics (NASDAQ:ARTV) was provided by Needham, and Artiva Biotherapeutics reiterated their buy rating.

There is no last upgrade for Artiva Biotherapeutics

There is no last downgrade for Artiva Biotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Artiva Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Artiva Biotherapeutics was filed on June 8, 2026 so you should expect the next rating to be made available sometime around June 8, 2027.

While ratings are subjective and will change, the latest Artiva Biotherapeutics (ARTV) rating was a reiterated with a price target of $41.00 to $41.00. The current price Artiva Biotherapeutics (ARTV) is trading at is $10.17, which is out of the analyst’s predicted range.